A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors

PURPOSE: To evaluate the safety, tolerability, pharmacokinetics, and efficacy of the intravenously administered pan-PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors. METHODS: A Phase I open-label study in Japanese patients with advanced or refractory solid tumo...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Chemother Pharmacol
Autori principali: Doi, Toshihiko, Fuse, Nozomu, Yoshino, Takayuki, Kojima, Takashi, Bando, Hideaki, Miyamoto, Hideaki, Kaneko, Masato, Osada, Motonobu, Ohtsu, Atsushi
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer Berlin Heidelberg 2016
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5225172/
https://ncbi.nlm.nih.gov/pubmed/27915408
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-016-3198-0
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi